Navigation Links
Company Announces Closure of Bluffton, Ohio Plant
Date:9/18/2007

HUTCHINSON, Kan., Sept. 18 /PRNewswire/ -- Collins Industries, a leading manufacturer of specialty vehicles in the United States, announced today the closing of the Mid Bus, Inc. production facility in Bluffton, Ohio. Company officials plan to move the Mid Bus production to their main facility in South Hutchinson, Kansas by November 9, 2007.

"The closure of the Mid Bus production facility in Bluffton, Ohio was certainly a difficult decision. Since the purchase of this company in 1998, we have enjoyed a good relationship with our employees and the community. However, with underutilized manufacturing capacity in our Kansas plant, coupled with recent manufacturing initiatives, we concluded that we could absorb excess volume and alleviate costly duplication of resources through moving the Mid Bus product line to Collins Bus Corporation in South Hutchinson, Kansas," stated Randall Swift, President/CEO of Collins Industries, Inc.

Company officials met with affected employees in the Bluffton, Ohio plant yesterday to announce the impending closure and to explain the intention of providing affected employees first consideration of any employment opportunities for which they are qualified at Collins Bus Corporation.

"As the leading manufacturer of Type-A buses in North America, it is incumbent upon us to continue to look for ways to provide our dealers and customers with the safest and best quality buses in the industry. Over the last nine months, we have made a substantial investment in our Kansas operation, which will allow us to increase our production capacity at the Collins Bus Corporation facility to over 4,000 units annually. We believe these types of changes will allow us to not only sustain our leading position in the Type-A market, but expand our market share and customer base in the coming years," stated Kent Tyler, President of Collins Bus Corporation.

Collins Industries, Inc., a subsidiary of BNS Holding, Inc. (OTC: BNSSA), is a leading manufacturer of ambulances (including medical attack vehicles, rescue vehicles and fire emergency vehicles), North America's largest producer of Type "A" small school buses, the nation's second largest manufacturer of terminal trucks and a leader in the road construction and industrial sweeper markets. Since 1971, the Company has grown to approximately 1000 employees in six plants comprising over one million combined square feet of manufacturing space. The Company sells its products throughout the United States and abroad.

This press release contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of assumptions, risks and uncertainties that could cause the actual results of the Company to differ materially from those matters expressed in or implied by such forward-looking statements. They involve known and unknown risks, uncertainties, and other factors, which are in some cases beyond the control of the Company. Additional information regarding these risk factors and uncertainties is described more fully in the Company's SEC filings. A copy of all SEC filings may be obtained from the SEC's EDGAR web site, http://www.sec.gov, or by contacting the company at (401) 848-6300. BNS does not currently maintain a web site.


'/>"/>
SOURCE Collins Industries, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Medicis Pharmaceutical company enters pediatric market
2. Problems Of a Growing Company
3. Teenagers Take More Risk-Taking Behaviors In The Company Of Same Sex Friends
4. British company developing ‘Safer Cigarettes
5. Australian Company Gets $10 million For Developing Skin Cancer Gel
6. Elderly People Prefer The Company Of Pet Dogs
7. Ossur Acquires the U.S. Orthopaedics Company
8. Britain Approves Indian Company For Supplying Medicines
9. Drug Company Admits Knowledge Of Side Effects In Monkeys
10. Ranbaxy Expands By Acquiring A Generic Company In Belgium
11. Indian Training Company To Train Children In Dubai, Sharjah
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2017)... MO (PRWEB) , ... September 26, 2017 , ... ... agreement for patient scales with Premier Inc. Effective October 1, 2017, the new ... and terms pre-negotiated by Premier for patient scales. , “DETECTO is pleased to ...
(Date:9/26/2017)... ... ... the Millennium”: a gripping take on how the author used personal experience to strengthen ... and do not affect daily choices. It shows how to act like the heirs ... are chosen. “How to Live in the Millennium” is the creation of published author, ...
(Date:9/26/2017)... ... ... “The Ballad of Cowboy Justin”: a charming tale of a brave cowboy who ... creation of published author, Leah Westbrook, a wife and mother who loves to spend ... a delightful tale about a young brave cowboy, Cowboy Justin, who saves the town ...
(Date:9/26/2017)... ... September 26, 2017 , ... “Childhood Memories of a Virginia Wanderer”: ... and help them relive their own youth. “Childhood Memories of a Virginia Wanderer” is ... US Navy for nine years. He received his BS from Idaho State University ...
(Date:9/26/2017)... ... September 26, 2017 , ... “The Tour Guide”: is the life story of the ... creation of published author, David Alexander Stark, is an adventure tour guide and the subject ... around to the back to confront fifteen shocked faces. I played it off as a ...
Breaking Medicine News(10 mins):
(Date:9/25/2017)...   Montrium , an industry leader in ... IQPC Trial Master Files & Inspection Readiness Conference ... Clinical Services has selected eTMF Connect ... EastHORN, a leading European contract research organization (CRO), ... to enable greater collaboration with sponsors, improve compliance ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., a ... design, and immune-engineering today announced the launch of ... development of personalized therapeutic cancer vaccines. EpiVax has ... exclusive access to enabling technologies to the new ... will lead EpiVax Oncology as Chief Executive Officer. ...
(Date:9/23/2017)... , Sept. 22, 2017 Janssen Biotech, Inc. ... response letter from the U.S. Food and Drug Administration ... of sirukumab for the treatment of moderately to severely ... additional clinical data are needed to further evaluate the ... severely active RA. ...
Breaking Medicine Technology: